# Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

> **NCT06075745** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 416 (estimated)

## Conditions studied

- Liver Transplant

## Interventions

- **DRUG:** CMV-MVA Triplex
- **DRUG:** Placebo for CMV-MVA Triplex

## Key facts

- **NCT ID:** NCT06075745
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075745, "Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06075745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*